Table 1.
Clinical characteristics and survival in patients with NSCLC treated with first-line targeted therapy or immunotherapy-based therapy: univariate log-rank analysis.
| Targeted Therapy Cohort | Immunotherapy Cohort | ||||||
|---|---|---|---|---|---|---|---|
| n = 159 | Overall Survival (months) | n = 230 | Overall Survival (months) | ||||
| All | n (%) | Median (IQR) | p | n (%) | Median (IQR) | p | |
| Age | ≤ 64 | 69 (43) | 21.9 (12.9–38.2) | 0.038 | 94 (41) | 10.0 (4.4–21.4) | 0.052 |
| 65–74 | 53 (33) | 15.3 (6.9–39.6) | 115 (50) | 17.6 (6.4–n/r) | |||
| >74 | 37 (23) | 12.9 (3.8–20.4) | 21 (9) | 13.9 (6.5–25.0) | |||
| Sex | Female | 51 (32) | 19.9 (8.2–39.4) | 0.319 | 115 (50) | 10.8 (4.7–n/r) | 0.204 |
| Male | 108 (68) | 17.7 (9.5–26.3) | 115 (50) | 17.4 (4.9–n/r) | |||
| Histologic Subtype | Squamous | 0 (0) | n/a | n/a | 44 (19) | 12.4 (4.6-n/r) | 0.600 |
| Non-Squamous | 159 (100) | 18.7 (8.8–38.2) | 186 (81) | 11.0 (7.0-n/r) | |||
| Treatment | Afatinib | 54 (34) | 20.2 (12.1–38.2) | 0.604 | n/a | n/a | 0.657 |
| Erlotinib | 62 (39) | 12.0 (6.7–26.8) | n/a | n/a | |||
| Osimertinib | 16 (10) | 16.5 (4.6–39.4) | n/a | n/a | |||
| Alectinib | 16 (10) | n/r | n/a | n/a | |||
| Crizotinib | 11 (7) | 17.7 (5.2–n/r) | n/a | n/a | |||
| Pembrolizumab | n/a | n/a | 167 (73) | 13.4 (4.5-n/r) | |||
| Chemo-immunotherapy | n/a | n/a | 63 (27) | 11.8 (6.4-18.9) | |||
| ECOG Performance Status | 0 | 30 (20) | 26.8 (16.2–39.4) | 0.002 | 37 (16) | n/r (10.1-n/r) | < 0.001 |
| 1 | 93 (58) | 18.5 (11.7–43.2) | 165 (72) | 13.4 (5.0-n/r) | |||
| 2+ | 36 (23) | 7.5 (3.5–21.6) | 28 (12) | 6.0 (2.1-10.4) | |||
| Albumin | ≥35g/L | 101 (64) | 21.9 (11.7–39.4) | 0.002 | 120 (52) | 19.7 (9.7-n/r) | < 0.001 |
| <35g/L | 58 (36) | 12.4 (4.4–21.9) | 110 (48) | 7.8 (2.5–20.5) | |||
n/r = not reached. Bold values are statistically significant variables.